Amgen revenue
Amgen's revenue was $36.75bn in fiscal 2025, up 10.0% on the year before. Since fiscal 2009 ($14.64bn) it has grown at a compound 5.9% a year. Over the last twelve months it was $38.09bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.6 | 15.1 | 15.6 | 17.3 | 18.7 | 20.1 | 21.7 | 23.0 | 22.8 | 23.7 | 23.4 | 25.4 | 26.0 | 26.3 | 28.2 | 33.4 | 36.8 | 38.1 |
| Growth on the year before | — | +2.8% | +3.5% | +10.8% | +8.2% | +7.4% | +8.0% | +6.1% | −0.6% | +3.9% | −1.6% | +8.8% | +2.2% | +1.3% | +7.1% | +18.6% | +10.0% | — |
| Gross profit | — | — | — | — | — | — | — | 18.8 | 18.8 | 19.6 | 19.0 | 19.3 | 19.5 | 19.9 | 19.7 | 20.6 | 24.7 | 26.5 |
| Gross margin | — | — | — | — | — | — | — | 81.9% | 82.2% | 82.7% | 81.4% | 75.8% | 75.2% | 75.7% | 70.0% | 61.5% | 67.2% | 69.5% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $35.1B | ▲ 9.7% |
| Other Products | $7.3B | ▲ 29.0% |
| Prolia | $4.4B | ▲ 0.9% |
| Repatha | $3B | ▲ 35.7% |
| Otezla | $2.3B | ▲ 6.5% |
| Enbrel | $2.2B | ▼ 32.9% |
| EVENITY | $2.1B | ▲ 34.4% |
| Xgeva | $2.1B | ▼ 6.3% |
| TEPEZZA | $1.9B | ▲ 2.8% |
| Other | $1.6B | ▲ 14.7% |
| BLINCYTO | $1.6B | ▲ 28.2% |
| Nplate | $1.5B | ▲ 4.7% |
| TEZSPIRE | $1.5B | ▲ 52.1% |
| KYPROLIS | $1.4B | ▼ 6.1% |
| Aranesp | $1.4B | ▲ 3.5% |
| KRYSTEXXA | $1.3B | ▲ 13.1% |
| Vectibix | $1.2B | ▲ 12.4% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $26.4B | 71.9% | ▲ 10.7% |
| Outside the US | $10.3B | 28.1% | ▲ 8.1% |
From Amgen's 10-K filed February 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Amgen | $38.09bn | 9.1% | 12.7% |
| Gilead Sciences | $30.99bn | 6.5% | 4.2% |
| AbbVie | $64.39bn | 10.4% | 4.7% |
| Regeneron Pharmaceuticals | $16.90bn | 18.6% | 8.9% |
| Vertex Pharmaceuticals | $12.59bn | 10.2% | 9.8% |
| Biogen | $10.30bn | 2.3% | 1.0% |
Compare with peers
- Gilead Sciences revenue
- AbbVie revenue
- Regeneron Pharmaceuticals revenue
- Vertex Pharmaceuticals revenue
- Biogen revenue
Head to head: AMGN vs GILDABBV vs AMGNAMGN vs REGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies